{"id":"hs-20094","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of HS-20094 has not been widely disclosed in public literature, it is being developed by Hansoh Pharmaceutical as an oncology agent in Phase 3 clinical trials. The compound likely functions through inhibition of a key signaling kinase to suppress tumor growth, though specific mechanistic details remain proprietary.","oneSentence":"HS-20094 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:01.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT07431086","phase":"PHASE2","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-16","conditions":"Overweight or Obesity","enrollment":120},{"nctId":"NCT07156539","phase":"PHASE3","title":"A Phase 3 Study of HS-20094 in Patients With T2DM","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-09-30","conditions":"Type 2 Diabetes","enrollment":546},{"nctId":"NCT07156500","phase":"PHASE3","title":"A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-09-30","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT06118008","phase":"PHASE2","title":"A Study of HS-20094 in T2DM Participants","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-05-31","conditions":"Type 2 Diabetes","enrollment":54},{"nctId":"NCT06901648","phase":"PHASE2","title":"A Study of HS-20094 in Patients With T2DM","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2024-02-06","conditions":"Type 2 Diabetes","enrollment":275},{"nctId":"NCT07057674","phase":"PHASE1","title":"A Study of HS-20094 in Overweight or Obese Participants","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-04-16","conditions":"Overweight or Obesity","enrollment":144},{"nctId":"NCT06839664","phase":"PHASE3","title":"A Study of HS-20094 in Chinese Adults with Overweight or Obesity","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2024-11-11","conditions":"Overweight, Obesity","enrollment":610},{"nctId":"NCT06118021","phase":"PHASE2","title":"A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-10-16","conditions":"Overweight and Obesity","enrollment":200},{"nctId":"NCT05116410","phase":"PHASE1","title":"A Study of HS-20094 in Healthy Participants","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-11-01","conditions":"Type 2 Diabetes","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HS-20094 injection"],"phase":"phase_3","status":"active","brandName":"HS-20094","genericName":"HS-20094","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-20094 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival pathways. Used for Oncology indication (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}